Senseonics Holdings (NASDAQ: SENS) saw its shares drop sharply by 5.26% during Monday's intraday session, despite the company reporting strong preliminary revenue growth for Q4 2025 and issuing optimistic guidance for 2026.
The medical technology company announced unaudited Q4 revenue of approximately $14.2 million, a 71% year-over-year increase, and full-year 2026 revenue guidance of $58-$62 million, representing growth of 65-76% over 2025. The decline in the stock price suggests investors may have been expecting even higher figures or opted to take profits after a recent rally.